Last reviewed · How we verify
Universidad Nacional de Rosario — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| paliperidone clozapine | paliperidone clozapine | marketed | Atypical antipsychotic | Dopamine D2 receptor, Serotonin 5-HT2A receptor | Psychiatry |
Therapeutic area mix
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Acacia Pharma Ltd · 1 shared drug class
- Alexza Pharmaceuticals, Inc. · 1 shared drug class
- Alkermes, Inc. · 1 shared drug class
- All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Benaroya Research Institute · 1 shared drug class
- BioXcel Therapeutics Inc · 1 shared drug class
- AbbVie · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Universidad Nacional de Rosario:
- Universidad Nacional de Rosario pipeline updates — RSS
- Universidad Nacional de Rosario pipeline updates — Atom
- Universidad Nacional de Rosario pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Universidad Nacional de Rosario — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-nacional-de-rosario. Accessed 2026-05-17.